Germany says vaccine rollout on track despite CureVac trial flop

A failure of German biotech CureVac to meet its efficacy goal in a late-stage trial for its COVID-19 vaccine will not impact the speed of Germany's vaccination rollout, the health ministry said on Thursday. "The announcement does not have an impact on the speed of our vaccination rollout," a health ministry spokesperson said, declining to comment on the study results. CureVac said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study's main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union.



from RSSMix.com Mix ID 8260652 https://ift.tt/3cNzxC8

Comments

Popular posts from this blog

Cards replace Yanks as White Sox opponent at Field of Dreams